UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934

Thomas Wetherald

49 Red Gate Lane

Cohasset, MA 02025

(585) 317-5667

With a copy to:

David R. Crandall

Hogan Lovells US LLP

1601 Wewatta Street, Suite 900

Denver, CO 80202

(303) 899-7300

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☒

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

This Schedule 13D relates to the common stock, $0.00001 par value per share (the “Common Stock”), of Taronis Fuels, Inc. (the “Issuer”). The principal executive office of the Issuer is 24980 N. 83rd Avenue, Suite 100, Peoria, Arizona 85383.

(a) This Schedule 13D is filed by:

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is party to that certain Joint Filing and Solicitation Agreement, as further described in Item 6. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

(b) The residence of Thomas Wetherald is 49 Red Gate Lane, Cohasset, Massachusetts 02025. The address of the principal office of Tobias Welo is 2 Newton Executive Park, Suite 202, 2227 Washington Street, Newton, Massachusetts, 02462.

(c) The principal occupation of Thomas Wetherald is a private investor. The principal occupation of Tobias Welo is Chief Executive Officer of Artful Jaunts, LLC, a travel company which offers trips focused on luxury art experiences, the principal address of which is 2 Newton Executive Park, Suite 202, 2227 Washington Street, Newton, Massachusetts, 02462.

(d) No Reporting Person has, during the last five (5) years, been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) No Reporting Person has, during the last five (5) years, been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

(f) Each of Thomas Wetherald and Tobias Welo is a citizen of the United States of America.

All of the shares of Common Stock to which this Schedule 13D relates were purchased on behalf of the Reporting Persons using their personal funds. The aggregate purchase price of the 933,333 shares of Common Stock acquired by the benefit of Thomas Wetherald was approximately $7,000,000. The aggregate purchase price of the 166,666 shares of Common Stock acquired by Tobias Welo and the trust for Mr. Welo’s children was approximately $1,250,000.

The Reporting Persons purchased the shares of Common Stock based on the Reporting Persons’ belief that the shares of Common Stock, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of shares of Common Stock at prices that would make the purchase or sale of shares of Common Stock desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of shares of Common Stock on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. The Reporting Persons may have conversations with members of the Issuer’s management and Board regarding possible ways to enhance shareholder value including through improvement in the Issuer’s capital allocation, operations, investor communications and corporate governance, among other topics.

The Reporting Persons, in the ordinary course of business, regularly review their equity interest in the Issuer and may, from time to time, acquire additional or sell shares of Common Stock.

Depending on their assessment of the foregoing factors, the Reporting Persons may, from time to time, modify their present intention as stated in this Item 4.

On February 12, 2021, the Reporting Persons filed a preliminary consent statement on Schedule 14A for the purpose of soliciting written consents to: (i) repeal any provision of the Issuer’s Amended and Restated Bylaws (the “Bylaws”) in effect at the time the proposal becomes effective, including any amendments thereto, which was not included in the Bylaws that were in effect as of December 13, 2019 and were filed with the SEC as Exhibit 3.2 to the Issuer’s amended Form 10 on December 13, 2019; (ii) amend Article IV, Section 18 of the Bylaws to declassify the Board so that all directors are elected on an annual basis; (iii) amend Article IV, Section 21 of the Bylaws to reduce the supermajority shareholder vote required to remove any individual director or directors from the Issuer’s Board from three-fourths of the then-outstanding shares of capital stock of the Issuer entitled to vote generally at an election of directors to a majority of the then-outstanding shares of capital stock of the Issuer entitled to vote generally at an election of directors; (iv) remove, without cause, all five members of the Issuer’s Board and, in addition, any person (other than those elected by proposal (v) below) nominated, elected or appointed to the Board to fill any vacancy on the Board or any newly-created directorships on or after December 20, 2020 and prior to the time that any of the actions proposed to be taken become effective; and (v) elect by consent in lieu of an annual meeting five nominees, including Thomas Wetherald and Tobias Welo, to serve as directors of the Issuer until the Issuer’s next annual meeting of shareholders and until their successors are duly elected and qualified (or, if any such nominee is unable or unwilling to serve as a director of the Issuer, or if the Board increases the number of directorships to be greater than five, any other person designated as a nominee by the remaining nominee(s)).

No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D, except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the shares of Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and the Board of the Issuer, engaging in discussions with shareholders of the Issuer and others about the Issuer and the Reporting Persons’ investment, making proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition) or operations of the Issuer, purchasing additional shares of Common Stock, selling some or all of their shares of Common Stock, engaging in short selling of or any hedging or similar transaction with respect to the shares of Common Stock, or changing their intention with respect to any and all matters referred to in Item 4.

The disclosures set forth in Item 3, Item 5 and Item 6 are incorporated by reference herein.

On February 12, 2021, the Reporting Persons entered into a Joint Filing and Solicitation Agreement for the purpose of, among other things (i) soliciting written consents or proxies in favor of proposals to reconstitute the Issuer’s Board of Directors and related bylaw amendments or other related actions, (ii) taking such other actions as the parties deem advisable and (iii) taking all other action necessary or advisable to achieve the foregoing. The Joint Filing and Solicitation Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.